A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

This is an open-label, Phase 1a dose escalation study of OMP-336B11 administered as a single
agent to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients
with locally advanced or metastatic tumors. This study consists of a screening period, a
treatment period, and a post-treatment follow-up period in which patients will be followed
for survival for up to approximately 2 years. Patients will be enrolled in two stages: a
dose-escalation stage and an expansion phase.

Inclusion Criteria:

- Locally advanced or metastatic solid tumors that have exhausted standard of care
therapy

- Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1

- Age >21 years

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Adequate organ and marrow function

- For women of childbearing potential and men with partners of childbearing potential,
agreement (by patient and/or partner) to use two effective forms of contraception from
study entry through at least 6 months after the termination visit.

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Receiving any other investigational agents or any other anti-cancer therapy

- Active autoimmune disease or a history of severe autoimmune disease or syndrome

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins

- Pregnancy, lactating or breastfeeding women

- History of primary CNS malignancy, or leptomeningeal disease or CNS metastases

- Significant uncontrolled intercurrent illness that will limit the patient's ability to
participate in the study

- Inability to comply with study and follow up procedures